Transcripts
Pfizer Inc.'s management answers for the business every quarter. These are the exchanges that explain it best — verbatim, from the call transcripts preserved in Sources. Each link opens the full transcript at that page in a new tab.
Q1 2026 Earnings Call — Q1 2026
The current thesis in one call: how a patent settlement reset the post-2028 growth story, and why a clear beat still didn't lift guidance. · Open the full transcript →
The Vyndamax patent settlement is the quarter's real news: it pushes a $6bn+ LOE out ~2.5 years and restores a post-2028 growth claim.
Albert Bourla (Chairman and CEO): We also had two significant legal developments that improved our growth profile post-2028 and, of course, our cash flow outlook. Our recent settlement agreements resolving infringement of patents related to Vyndamax have the potential to change the growth profile of the company significantly post-2028. This gives us greater confidence that starting in 2029, we will enter a five-year period of high singledigit revenue CAGR.
p. 1 · Read in context →
The print and the offset engine: $14.5bn revenue, ~7% ex-COVID, and $3.1bn of launched/acquired products (+22%) meant to blunt the LOEs.
David Denton (CFO): In the first quarter of '26, revenues were $14.5 billion, exceeding our expectations and representing an operational increase of 2%. Excluding our COVID products, the underlying business delivered approximately 7% operational revenue growth […] Our launch and acquired products delivered $3.1 billion in the first quarter revenues and grew by approximately 22% operationally. […] We continue to invest behind these product groups to support their growth, which we expect will enable the company to partially offset upcoming LOE headwinds over the next several years.
p. 3 · Read in context →
Why a clear beat didn't lift the guide: Denton won't raise after Q1, citing COVID's back-half seasonality as the reason to hold.
Christopher Schott (JPMorgan); David Denton (CFO): I know you typically don't raise guidance with 1Q, but this seems like a very solid start to the year from a revenue perspective. […] As you well know, Chris, I have a philosophy of not adjusting guidance in Q1. If you look at our COVID franchise, it will always be back-half weighted because of the seasonality. So we have, if anything, de-risked delivery on that without raising guidance. So absent COVID seasonality, we might be raising guidance.
p. 6 · Read in context →
Q4 & Full-Year 2025 Earnings Call — Q4 2025
The clearest single view of the repositioning: the four priorities, the obesity bet, and how 2025's cash was allocated. · Open the full transcript →
The strategic frame for the cliff years: Seagen, Metsera and Biohaven as the offset, and obesity aimed at a ~$150bn market.
Albert Bourla (Chairman and CEO): 2026 is an important year in a pivotal investment period as we strive for industry-leading growth after several key products lose patent or regulatory exclusivity in the next few years. Seagen, Metsera, and Biohaven are the most significant strategic acquisitions in recent years. They have transformative potential for Pfizer Inc. […] The foundation of our strategy in obesity and adjacent conditions is targeting breakthrough medicines in what could be a $150 billion market.
p. 1 · Read in context →
FY2025 scorecard: $62.6bn revenue (-2% op, +6% ex-COVID) and $10.2bn of launched/acquired products growing 14% to backfill LOEs.
Dave Denton (CFO): For the full year 2025, we recorded revenues of $62.6 billion versus $63.6 billion last year, representing a 2% operational decline. Importantly, our operational revenue growth, when excluding contributions from our COVID-19 products, was 6%. […] Pfizer Inc.'s recently launched and acquired set of products delivered $10.2 billion in revenues for the full year of 2025 while growing approximately 14% operationally versus last year.
p. 4 · Read in context →
Where the cash went in 2025: $9.8bn dividend, $10.4bn internal R&D, $8.8bn of BD (mostly Metsera) — dividend first, buybacks later.
Dave Denton (CFO): In 2025, we returned $9.8 billion to shareholders via the quarterly dividend, invested $10.4 billion in internal R&D, and invested approximately $8.8 billion in business development transactions, primarily reflecting the Metsera acquisition and the 3S Bio licensing deal.
p. 6 · Read in context →
The obesity economics few discuss: ~40% of the $150bn market is ex-US, much of it cash-pay at $250-350, enabling faster launches.
Alexandre de Germay (President, International Developed Markets): What's really interesting in this category is actually the size of the market ex-US projected to be $150 billion, and 40% of that is actually ex-US. […] we see that there is high willingness to pay out of pocket across all mature markets, either in Europe or Australia or in Canada, and we see the price point being across $250 to $350, which is higher than what we had expected.
p. 7 · Read in context →
Q3 2023 Earnings Call — Q3 2023
The credibility test: management quantifies the COVID collapse and lays out the cost-cut-and-acquire response that defines today's Pfizer. · Open the full transcript →
The COVID unwind laid bare: the US returns 7.9m Paxlovid courses for $4.2bn of future revenue with no cash — the shock behind the reset.
Dave Denton (CFO): Before I review this quarter's results, I will address a couple of topics that have been top of mind with investors since our announcement on October 13. These topics relate to our future U.S. government Paxlovid revenue forecasts, as well as our multiyear cost realignment program. […] As a result of all of that, Pfizer has an obligation to deliver an estimated 8.9 million treatment courses for which we will record an approximately $4.2 billion of revenue beginning in 2024 as we deliver treatment courses. It is important to note that there is no cash compensation for the estimated 8.9 million treatment courses delivered.
p. 7 · Read in context →
Funding the pivot while cutting: $43bn committed to Seagen even as costs are slashed; buybacks wait until the balance sheet delevers.
Dave Denton (CFO): In the first nine months of 2023, we invested $7.9 billion in internal R&D, returned $6.9 billion to shareholders via our quarterly dividend, and allocated approximately $43 billion toward the proposed Seagen acquisition. […] And as we delever, we anticipate returning to a more balanced capital allocation strategy, inclusive of share repurchases.
p. 9 · Read in context →
Q4 2021 Earnings Call — Q4 2021
The peak call that set everything in motion: the $100bn COVID windfall and the plan to spend it on becoming a growth company. · Open the full transcript →
The peak, in management's words: a first-ever $100bn revenue midpoint for 2022 and a claim the COVID work changed the company for good.
Albert Bourla (Chairman and CEO): Our success in leading the fight against COVID-19 have not only made a positive difference in the world. I believe they have fundamentally changed our company and our culture forever. […] Our full year 2022 financial guidance, for example, includes, for the first time ever, a forecasted revenue midpoint, that it is triple-digit, $100 billion, and an adjusted diluted EPS midpoint of $6.45.
p. 4 · Read in context →
The playbook that defined the next five years: redeploy COVID cash into BD to stay a growth company, targeting +$25bn of 2030 revenue.
Albert Bourla (Chairman and CEO): Our goal is to continue to be a growth company from '25 to 2030, despite the impact of LOEs expected during that period. […] The strength of our balance sheet and cash flows allow us to pursue new business development opportunities going forward that could add at least $25 billion of risk-adjusted revenues to our 2030 top-line expectations.
p. 7 · Read in context →
The seeds, named early: Trillium, Biohaven (now Nurtec) and Arena (etrasimod) — deals that became today's growth portfolio.
Albert Bourla (Chairman and CEO): The acquisition of Trillium builds on our strong track record of leadership in oncology, enhancing our hematology portfolio […] Our strategic collaboration with Biohaven leverages our leading commercial capabilities in pain and women's health, with Biohaven's groundbreaking oral CGRP receptor antagonist […] And through our proposed acquisition of Arena, we plan to leverage Pfizer's leading research and global development capabilities to accelerate the clinical development of etrasimod
p. 10 · Read in context →
More calls
Q3 2025 Earnings Call — Q3 2025 · 12 pages · Where the Metsera obesity acquisition was won over Novo Nordisk's counterbid, and where the US MFN drug-pricing/tariff framework was settled with a grace period. · Open →
Q2 2025 Earnings Call — Q2 2025 · 16 pages · The tariff and Most-Favored-Nation pricing scare at its peak — the July 2025 policy letters and how management framed the Section 232 risk. · Open →
Q1 2025 Earnings Call — Q1 2025 · 5 pages · The obesity reset: the oral GLP-1 danuglipron was discontinued here, and the initial FY2025 guide was set before the Metsera pivot. · Open →
Q4 & Full-Year 2023 Earnings Call — Q4 2023 · 51 pages · The first full guidance of the reset era, with Seagen just closed — the reader gets the original 2024 rebuild framework. · Open →
Q1 2023 Earnings Call — Q1 2023 · 52 pages · The first earnings call after the $43bn Seagen announcement — how management first justified the oncology bet to analysts. · Open →
Q4 & Full-Year 2022 Earnings Call — Q4 2022 · 51 pages · The COVID-to-normal transition framing — 2023 set up as the year Pfizer pivoted from pandemic peak to base-business growth. · Open →